Table 3.
Overview of the population characteristics from observational studies
| Study | Sample (COVID-19/HIV-coinfected patients), n | Age (mean), yr | Sex, n | CD4 cell count, (>200 cells/ mm3) n | HIV viral load, (<50 copies/ mL) n | Severe/critical cases, n | Comorbidities | Symptoms | Antiretroviral drugs |
|---|---|---|---|---|---|---|---|---|---|
| Altuntas Aydin et al., 2020 [19] | 4 | 37.2 | M: 4 | 3 | 3 | 1 | HTN, DM, BMI>30 kg/m2 | Fever, cough, dyspnoea | NRTI, INSTI |
| Blanco et al., 2020 [20] | 5 | 37.8 | M: 3, F: 2 | 5 | 4 | 2 | Hypothyroidism, asthma | Fever, cough, dyspnoea | PI, INSTI |
| Childs et al., 2020 [21] | 18 | 52.0 | M: 12, F: 6 | 18 | 17 | 5 | HTN, DM, RD, BMI>30 kg/m2 | Fever, cough, dyspnoea | NRTI, NNRTI, PI, INSTI |
| Del Amo et al., 2020 [22] | 236 | 47.0 | M: 204, F: 32 | U | U | 15 | U | U | NRTI, NNRTI, PI, INSTI |
| Etienne et al., 2020 [23] | 54 | 54.0 | M: 33, F: 21 | 51 | 51 | 19 | HTN, DM, RD, CVD, RPD, LD, neoplasm, BMI>30 kg/m2 | U | NRTI, NNRTI, PI, INSTI |
| Gervasoni et al., 2020 [24] | 47 | 51.0 | M: 36, F: 11 | 36 | 44 | 6 | HTN, DM, RD, CVD, LD, RPD, neoplasm | Fever, cough, dyspnoea | NRTI, PI, INSTI |
| Gudipati et al., 2020 [25] | 14 | 49.0 | M: 12, F: 2 | 12 | 13 | 2 | HTN, DM, RD, CVD, RPD, BMI>30 kg/m2 | Fever, cough, dyspnoea | NRTI, PI |
| Guo et al., 2020 [10] | 11 | 53.2 | M: 10, F: 1 | 9 | 9 | 5 | 6 cases with comorbidities | U | NRTI, NNRTI, PI |
| Härter et al., 2020 [26] | 33 | 48.0 | M: 30, F: 3 | 31 | 30 | 8 | HTN, DM, RD, CVD, RPD, LD | Fever, cough, dyspnoea | NRTI, NNRTI, PI, INSTI |
| Hu et al., 2020 [27] | 12 | 36.0 | M: 10, F: 2 | 12 | 8 | 2 | HTN, RD, RPD | U | NRTI, NNRTI |
| Huang et al., 2020 [28] | 35 | 52.0 | M; 33, F: 2 | 30 | 22 | 15 | U | U | NRTI, NNRTI |
| Liu et al., 2020 [29] | 20 | 46.5 | M: 5, F: 15 | U | U | 3 | HTN, DM, CVD, RPD, LD | Fever, cough, dyspnoea | NRTI, NNRTI, PI |
| Meyerowitz et al., 2020 [30] | 36 | 53.4 | U | 34 | U | 15 | HTN, DM, RD, BMI>30 kg/m2 | U | NRTI, NNRTI, PI, INSTI |
| Nagarakanti et al., 2021 [31] | 23 | 59.0 | M: 14, F: 9 | 20 | U | 2 | HTN, DM, RD, CVD, RPD | Fever, cough, dyspnoea | NRTI, NNRTI, PI, INSTI |
| SeyedAlinaghi et al., 2020 [33] | 1 | 40.5 | M: 1 | N | 1 | N | N | Fever, cough, dyspnoea | NRTI, PI |
| Sigel et al., 2020 [34] | 88 | 61.0 | M: 66, F: 22 | 64 | 66 | 18 | HTN, DM, RD, LD, RPD, neoplasm, BMI>30 kg/m2 | U | NRTI, NNRTI, PI, INSTI |
| Stoeckle et al., 2020 [35] | 30 | 60.5 | M: 24, F: 6 | 20 | 27 | 4 | HTN, DM, RD, CVD, LD, RPD, | Fever, cough, dyspnoea | NRTI, PI |
| Sasset et al., 2020 [32] | 2 | 61.2 | M: 2 | 2 | 2 | 2 | HTN, CVD, LD, BMI>30 kg/m2 | U | PI |
| Swaminathan et al., 2021 [36] | 6 | 64.0 | M: 5, F: 1 | 6 | 5 | 2 | HTN, DM, RD, CVD, RPD, BMI>30 kg/m2 | U | INSTI |
| Tian et al., 2021 [37] | 1 | 24.0 | M: 1 | 1 | U | N | U | U | PI |
| Vizcarra et al., 2020 [38] | 51 | 53.3 | M: 43, F: 8 | 27 | 50 | 6 | HTN, DM, RD, CVD, LD, RPD, neoplasm, BMI>30 kg/m2 | Fever, cough, dyspnoea | NRTI, NNRTI, PI, INSTI |
| Yang et al., 2021 [39] | 3 | 40.0 | M: 3 | 2 | U | N | U | U | NRTI, NNRTI, INSTI |
U, unknown; N, null; HTN, hypertension; DM, diabetes mellitus; RD, renal disease; CVD, cardiovascular disease; BMI, body mass index; LD, liver disease; RPD, respiratory disease; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase strand transfer inhibitor; M, male; F, female.